Résultats de la recherche
10
Tout
Rechercher les filtres
Organisation
Humacyte, Inc
Humacyte Second Quarter 2022 Financial Results and Business Update
12 août 2022 07h00 HE
|
Humacyte, Inc
-- Human Acellular Vessels™ (HAVs™) successfully implanted in wounded Ukrainian citizens and reported to be functioning, saving limbs – -- Hosted key opinion leader (KOL) webinar on HAV in the...
Humacyte to Present Second Quarter 2022 Financial Results and Provide Recent Corporate Update on August 12, 2022
05 août 2022 08h00 HE
|
Humacyte, Inc
DURHAM, N.C., Aug. 05, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Preclinical Data on Small-Diameter Human Acellular Vessel™ (HAV™) in Coronary Artery Bypass Grafting (CABG) Presented at American Heart Association Meeting
25 juil. 2022 20h26 HE
|
Humacyte, Inc
-- Preclinical model data expected to support development of small diameter HAV to treat patients with coronary artery disease-- -- Small-diameter HAV observed to maintain patency and exhibit...
Humacyte Announces Presentation of Preclinical Data on the HAV™ in Coronary Artery Bypass Grafting at the Basic Cardiovascular Sciences Scientific Sessions
19 juil. 2022 08h00 HE
|
Humacyte, Inc
DURHAM, N.C., July 19, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues, today...
Humacyte Hosting Key Opinion Leader Webinar on Human Acellular Vessels™ in the Treatment of Vascular Trauma
07 juil. 2022 08h00 HE
|
Humacyte, Inc
DURHAM, N.C., July 07, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Announces JAMA Surgery Publication Highlighting Potential of Human Acellular Vessel™ (HAV™) to Expand Vascular Trauma Reconstruction and Bypass Treatment Options
29 juin 2022 08h00 HE
|
Humacyte, Inc
-- HAV implanted in nearly 500 patients with more than 1,000 patient-years of follow up to date, for treatment of peripheral arterial disease, arteriovenous access for hemodialysis, and trauma – --...
Humacyte Expands Board of Directors with Appointment of Diane Seimetz, Ph.D.
27 juin 2022 07h30 HE
|
Humacyte, Inc
DURHAM, N.C., June 27, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...
Humacyte Provides Update on Patients Treated at Front-Line Hospitals in Ukraine with the Human Acellular Vessel™ (HAV™) for Repair of Vascular Trauma Injuries
21 juin 2022 07h30 HE
|
Humacyte, Inc
-- Successful first two HAV implantations in wounded Ukrainian citizens -- HAVs were provided under Humacyte’s initiative to assist Ukraine humanitarian medical effort -- Provides further real-world...
Humacyte Presents New Immunogenicity Data on Human Acellular Vessels™ (HAVs™)
08 juin 2022 08h00 HE
|
Humacyte, Inc
-- Data indicate HAV does not stimulate increase in panel reactive antibodies, an adaptive immune response correlated with increased risk of implant failure -- -- Data presented today in IMPACT...
Humacyte to Present at the H.C. Wainwright Global Investment Conference
16 mai 2022 08h00 HE
|
Humacyte, Inc
DURHAM, N.C., May 16, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at...